Syndax Pharmaceuticals

Earlier this week, the Syndax team attended the 2024 Annual Meeting of the American College of Clinical Pharmacology?, where we had the privilege of presenting a poster exploring the pharmacokinetics and exposure-response relationship of investigational revumenib in patients with relapsed/refractory acute leukemias.?? ? This was an exceptional opportunity to join other industry innovators committed to harnessing the power of clinical pharmacology.? ? Learn more: https://lnkd.in/eeCP7D5r ?

#DYK that Syndax’s logo is made up of colorful birds? In this short video, Jill explains how the Syndax Flock–prominently featured in our logo–symbolizes the collaboration, innovation and commitment to excellence that mirrors birds uniting in flight to reach their destination. #WeFlyHigherTogether

We’re pleased to have participated in #SOHO2024, where we had the opportunity to come together with other industry leaders to learn about new advances and practical clinical applications in the field of hematologic malignancies. Until next year!

#ICYMI: Earlier this month, Syndax marked a major milestone with our first FDA approval for Niktimvo? (axatilimab-csfr). In this short video, Peter Ordentlich, Chief Scientific Officer and Founder, dives into the origin of axatilimab-csfr and how Syndax followed compelling science to develop this therapeutic candidate. Thank you, Peter, for your critical role in shepherding axatilimab-csfr through the drug development process. Tune in to learn more:?

On #WorldLeukemiaDay, we join hands with patients, their families and caregivers worldwide impacted by this devastating disease to raise awareness, advance advocacy efforts, and bring together the international leukemia community. We invite you to walk with Syndax during The Leukemia & Lymphoma Society’s #LightTheNight event to play a part in transforming the landscape of cancer. Learn more: https://lnkd.in/grFsyVWK

#DYK that every three minutes, someone in the U.S. is diagnosed with a type of blood cancer? September is #BloodCancerAwarenessMonth, a global event that was established to shine a light on the importance of finding cures for the millions of people affected by this group of diseases. This year, we’re proud to be partnering with The Leukemia & Lymphoma Society for #LightTheNight, a series of events supporting the advancement of life-changing research. Join our team and walk with Syndax: https://lnkd.in/grFsyVWK

Society of Hematologic Oncology’s #SOHO2024 kicks off tomorrow in Houston, Texas! Visit Syndax at Booth 117 to learn how we are reimagining #cancer care. Catch all the details here:?https://lnkd.in/gCyfK8FN

Childhood Cancer Awareness Month is a time to celebrate advances in research for pediatric patients, pay tribute to those we have lost, and continue to emphasize the importance of research for potential cures. Last month, we had the privilege of hosting Joe McDonough from The Andrew McDonough B+ Foundation, which honors the life and memory of Andrew McDonough, who lost his life at 14-years-old to acute myeloid leukemia. Childhood cancer is pervasive, with 46 children in the U.S. diagnosed with cancer every day. Learn how B+ is working to change these statistics: https://lnkd.in/eFmQRAHJ

Recently, Syndaxers gathered at Yankee Stadium for a lively summer outing to close out our 2024 internship program. It was a fantastic time to connect with one another, celebrate our interns, and cheer on the Yankees! ? Thank you to everyone who attended. Until next year!? ? #TeamBuilding?#WeFlyHigherTogether

We’re excited to announce a landmark achievement for Syndax and our partners at Incyte. Niktimvo (axatilimab-csfr) is now U.S. FDA-approved! We would like to extend our appreciation to the clinicians, investigators, Syndax and Incyte employees, and patients who made our first-ever approval possible. Learn more by reading our press release and tuning in to our live webcast today at?6:00 p.m. ET:??https://lnkd.in/gjDqy_7v